New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma
Today, it is difficult to overestimate the new directions in the pharmacotherapy of peripheral T-cell lymphomas (PTCL): immunotherapy, including adoptive, targeted therapy and chemotherapy. However, there are few biomarkers that predict response to therapy. A big problem is patients with refractory...
Main Authors: | M. А. Sorokina, A. V. Rakhteenko, T. R. Grishina |
---|---|
格式: | 文件 |
语言: | Russian |
出版: |
IRBIS LLC
2023-07-01
|
丛编: | Фармакоэкономика |
主题: | |
在线阅读: | https://www.pharmacoeconomics.ru/jour/article/view/807 |
相似书籍
-
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
由: Francine Foss, et al.
出版: (2016-03-01) -
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
由: Cinzia Pellegrini, et al.
出版: (2016-04-01) -
MYCOSIS FUNGOIDES PROGRESSING TO PERIPHERAL T-CELL LYMPHOMA AND THE POTENTIAL ROLE OF ROMIDEPSIN THERAPY
由: Bengisu Ece Duman, et al.
出版: (2024-12-01) -
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
由: Guang Lu, et al.
出版: (2023-08-01) -
Interleukin-6 mediates resistance to PI3K-pathway–targeted therapy in lymphoma
由: Joo Hyun Kim, et al.
出版: (2019-10-01)